CClinicalTrials.gg
Not yet recruitingNCT06489366Updated Jul 5, 2024

Efficacy of Semi-rigid Ureteroscopic Laser Lithotripsy in the Treatment of Proximal Ureteral Stones: a Randomized Controlled Trial

An interventional study of Thulium Fiber laser (TFL) lithotripsy and Ho: YAG lithotripsy in Urolithiasis and Proximal Ureteral Stone, sponsored by Zhongnan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by Zhongnan Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The efficacy of Ho: YAG and TFL combined with semirigid ureteroscopic treatment of proximal ureteral stones will be compared.

Read the detailed description

The target population of this study is patients with proximal ureteral stones who are scheduled to undergo semirigid ureteroscopic laser lithotripsy. After enrollment, the subjects will be randomly assigned to the semirigid ureteroscopic holmium laser (Ho: YAG) lithotripsy group and the semirigid ureteroscopic thulium fiber laser (TFL) lithotripsy group for surgical treatment. The subjects will be followed up after surgery, and the collected data will be summarized and analyzed after the study.

02

Conditions studied

  • Urolithiasis
  • Proximal Ureteral Stone

Keywords

  • Proximal ureteral stones
  • Ho: YAG lithotripsy
  • Thulium Fiber laser (TFL) lithotripsy
  • Semirigid ureteroscopic lithotripsy
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. ≥18 years old;
  2. patients diagnosed with unilateral proximal ureteral stones ≤2cm by computed tomography (CT)/Kidney and upper bladder (KUB) radiography who required surgery;
  3. patients who volunteered to participate in this study.

Exclusion criteria

Exclusion Criteria:

  1. Unable to give informed consent;
  2. Untreated urinary tract infection;
  3. Pregnant women;
  4. Known anatomical abnormalities (such as urinary diversion or ureteral stenosis);
  5. Urothelial tumors, transplanted kidney stones, irreversible coagulopathy;
  6. The semi-rigid ureteroscope cannot reach the stone site, ureteroscopy-negative stones, and stones can be removed directly without laser lithotripsy;
  7. The researchers believe that they are not suitable for participation in this study.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
138 participants (estimated)

Study arms

  • Active comparator
    Ho: YAG lithotripsy

    Ho; YAG laser therapy device is used. The patient adopts lithotomy position. After general anesthesia, a semi-rigid ureteroscope is used to enter the bladder through the urethra to observe the ureteral opening, and then a hydrophilic guide wire is inserted into the ureter on the affected side. After the semi-rigid ureteroscope slowly enters along the hydrophilic guide wire and reaches the bottom of the stone, the laser optical fiber of the laser therapy device is inserted into the working channel of the ureteroscope so that the end of the optical fiber is exposed in the field of view of the ureteroscope. After the laser therapy device sets the lithotripsy parameters, the optical fiber is aimed at the stone for laser lithotripsy.

    Device: Ho: YAG lithotripsy

  • Experimental
    Thulium Fiber laser (TFL) lithotripsy

    The patient adopts lithotomy position. After general anesthesia, a semi-rigid ureteroscope is used to enter the bladder through the urethra to observe the ureteral opening, and then a hydrophilic guide wire is inserted into the ureter on the affected side. After the semi-rigid ureteroscope slowly enters along the hydrophilic guide wire and reaches the bottom of the stone, the laser fiber of the laser therapy machine is inserted into the working channel of the ureteroscope so that the end of the fiber is exposed to the field of view of the ureteroscope. Using the TFL laser therapy device, after setting the lithotripsy parameters, the fiber is aimed at the stone for laser lithotripsy.

    Device: Thulium Fiber laser (TFL) lithotripsy

Interventions

  • DeviceThulium Fiber laser (TFL) lithotripsy

    Patients with proximal ureteral stones undergoing ureteroscopic lithotripsy using thulium laser lithotripsy.

  • DeviceHo: YAG lithotripsy

    Ho:YAG laser lithotripsy was used in patients with proximal ureteral stones undergoing ureteroscopic lithotripsy.

05

What researchers measure

Primary outcomes

  1. Stone-free rate (SFR)

    Stone-free rate (SFR) after single-session laser lithotripsy using a semirigid ureteroscope without an auxiliary procedure assessed by CT/X-ray at 2-4 weeks follow-up after laser lithotripsy.

    Time frame: 2-4 weeks after surgery

Secondary outcomes

  1. Operative time

    the time of laser lithotripsy

    Time frame: Immediately during surgery

  2. Intraoperative complications

    bleeding, ureteral perforation, ureteral wall injury, or intraoperative adverse events leading to termination of surgery

    Time frame: Immediately during surgery

  3. Postoperative complications

    Occurrence of postoperative complications

    Time frame: 2-4 weeks after surgery

  4. Additional procedures

    If semi-rigid ureteroscopy combined with laser lithotripsy fails, it is converted to flexible ureteroscopy, PCNL, laparoscopic lithotomy. In addition, ESWL treatment is performed before the double-J stent is removed after surgery.lithotripsy, and postoperative ESWL treatment before removal of the ureteral stents, among others.

    Time frame: Intraoperatively and before removal of the Ureteral stents

06

Study locations

1 site
  • Zhongnan Hospital, Wuhan University,
    Wuhan, Hubei 430071, China
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06489366
Lead sponsor
Zhongnan Hospital
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Jun 26, 2024 (estimated)
Primary completion
Jan 26, 2025 (estimated)
Completion
Feb 26, 2025 (estimated)
Last update
Jul 5, 2024

Study contacts

Xinghuan Wang
Contact
wangxinghuan@whu.edu.cn
+86 18770426026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion